Kyverna Therapeutics Share Price Today
(NASDAQ: KYTX)

Name: Kyverna Therapeutics Share Price Today (NASDAQ: KYTX) - Kyverna Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Kyverna Therapeutics share price is $2.66 & ₹231.34 as on 6 Mar 2025, 2.30 'hrs' IST

$2.66

▲

0.03

(1.14%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Kyverna Therapeutics share price in Dollar and Rupees. Guide to invest in Kyverna Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Kyverna Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Kyverna Therapeutics share price movements

Today's Low: $2.54
Today's High: $2.77
$2.66
4.51%
Downside
Day's Volatility :8.44%
Upside
4.11%
52 Weeks Low: $2.59
52 Weeks High: $30.60
$2.66
2.63%
Downside
52 Weeks Volatility :91.54%
Upside
91.31%

Kyverna Therapeutics (KYTX) Returns

Period	Kyverna Therapeutics	Index (Russel 2000)
3 Months	-43.44%	0.0%
6 Months	-65.3%	0.0%
1 Year	-90.69%	0.0%
3 Years	-91.23%	-11.6%

Kyverna Therapeutics (KYTX) Key Statistics

in dollars & INR

Previous Close	$2.63
Open	$2.78
Today's High	$2.774
Today's Low	$2.54
Market Capitalization	$111.8M
Today's Volume	$64.7K
52 Week High	$30.6
52 Week Low	$2.54
Revenue TTM	$0.0
EBITDA	$-119.1M
Earnings Per Share (EPS)	$-2.96
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-59.58%

How to invest in Kyverna Therapeutics Stock (KYTX) from India?

It is very easy for Indian residents to invest directly in Kyverna Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Kyverna Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Kyverna Therapeutics or KYTX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Kyverna Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Kyverna Therapeutics shares which would translate to 0.327 fractional shares of Kyverna Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Kyverna Therapeutics, in just a few clicks!

Returns in Kyverna Therapeutics (KYTX) for Indian investors in Rupees

The Kyverna Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Kyverna Therapeutics investment value today

Current value as on today

₹14,375

Returns

₹85,625

(-85.62%)

Returns from Kyverna Therapeutics Stock

₹90,587 (-90.59%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Kyverna Therapeutics (KYTX)

-43%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Kyverna Therapeutics Stock from India on INDmoney has decreased by -43% in the last 30 days, reflecting a downward trend in search activity.

Analyst Recommendation on Kyverna Therapeutics

Buy

90%Buy

10%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Kyverna Therapeutics(by analysts ranked 0 to 5 stars)

Analyst Forecast on Kyverna Therapeutics Stock (KYTX)

What analysts predicted

Upside of 783.46%

Target:

$23.50

Current:

$2.66

Insights on Kyverna Therapeutics Stock (Ticker Symbol: KYTX)

Price Movement
In the last 3 months, KYTX stock has moved down by -43.4%
KYTX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 152.9%

Kyverna Therapeutics Technicals Summary

Sell

Neutral

Buy

Kyverna Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Kyverna Therapeutics (KYTX) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Kyverna Therapeutics	-15.16%	-65.3%	-90.69%	-91.23%	-91.23%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Kyverna Therapeutics	NA	NA	NA	-3.23	-0.6	-0.35	NA	7.01
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Kyverna Therapeutics	Buy	$111.8M	-91.23%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Kyverna Therapeutics

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Organization	Kyverna Therapeutics
Employees	119
CEO	Mr. Warner Biddle
Industry	Miscellaneous

Management People of Kyverna Therapeutics

Name	Title
Ms. Karen Walker	Chief Technology Officer
Mr. Warner Biddle	CEO & Director
Mr. Ryan Jones M.B.A.	Chief Financial Officer
Dr. Tom Van Blarcom Ph.D.	Senior VP & Head of Research
Ms. Tracy Rossin	Senior Vice President of Corporate Affairs & Communications and Investor Relations
Ms. Cara Bauer	Chief Human Resources Officer
Dr. Dominic Borie M.D., Ph.D.	President of Research & Development
Mr. Devin Murray	Senior Vice President of Partnerships & Alliances
Mr. Dan Maziasz	Chief Business Officer
Dr. Naji Gehchan M.B.A., M.D.	Chief Medical & Development Officer

Important FAQs about investing in KYTX Stock from India :

What is Kyverna Therapeutics share price today?

Kyverna Therapeutics share price today stands at $2.66, Open: $2.78 ; Previous Close: $2.63 ; High: $2.77 ; Low: $2.54 ; 52 Week High: $30.60 ; 52 Week Low: $2.59.

The stock opens at $2.78, after a previous close of $2.63. The stock reached a daily high of $2.77 and a low of $2.54, with a 52-week high of $30.60 and a 52-week low of $2.59.

Can Indians buy Kyverna Therapeutics shares?

Yes, Indians can invest in the Kyverna Therapeutics (KYTX) from India.

With INDmoney, you can buy Kyverna Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Kyverna Therapeutics at zero transaction cost.

How can I buy Kyverna Therapeutics shares from India?

It is very easy to buy Kyverna Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Kyverna Therapeutics (KYTX) be purchased?

Yes, you can buy fractional shares of Kyverna Therapeutics with INDmoney app.

What are the documents required to start investing in Kyverna Therapeutics stocks?

To start investing in Kyverna Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.